THE ONLY FXa INHIBITOR ANTIDOTE*

Please join us for a presentation on

Latest Data on Management of Factor Xa Inhibitor-Related Acute Major Bleeding

September 7, 2023 | 06:30 PM – 09:30 PM Central Daylight Time

PRESENTED BY
Dr. Luis Fernandez
Medical Director, Trauma Wound Care, Professor of Surgery
University of Texas Health Science Center, Tyler, Texas

LOCATION
Prime 102
102 North College Avenue
Tyler, TX 75702

To find out more information or to register, please contact **Corey Baker at (817) 703-5806 or courtney.baker@astrazeneca.com.**

*ANDEXXA has not been shown to be effective for, and is not indicated for, the treatment of bleeding related to any FXa inhibitors other than apixaban or rivaroxaban.

IMPORTANT SAFETY INFORMATION FOR ANDEXXA® (coagulation factor Xa [recombinant], inactivated-zhzo)

WARNING: THROMBOEMBOLIC RISKS, ISCHEMIC RISKS, CARDIAC ARREST, AND SUDDEN DEATHS

Treatment with ANDEXXA has been associated with serious and life-threatening adverse events, including:

- **Arterial and venous thromboembolic events**
- **Ischemic events, including myocardial infarction and ischemic stroke**
- **Cardiac arrest**
- **Sudden deaths**

Monitor for thromboembolic events and initiate anticoagulation when medically appropriate. Monitor for symptoms and signs that precede cardiac arrest and provide treatment as needed.

WARNINGS AND PRECAUTIONS

- Arterial and venous thromboembolic events, ischemic events, and cardiac events, including sudden death, have occurred during treatment with ANDEXXA. To reduce thromboembolic risk, resume anticoagulant therapy as soon as medically appropriate following treatment with ANDEXXA. The safety of ANDEXXA has not been evaluated in subjects who experienced thromboembolic events or disseminated intravascular coagulation within two weeks prior to the life-threatening bleeding event requiring treatment with ANDEXXA. Safety of ANDEXXA also has not been evaluated in subjects who received prothrombin complex concentrates, recombinant factor VIIa, or whole blood products within seven days prior to the bleeding event.
- Re-elevation or incomplete reversal of anticoagulant activity can occur.
- ANDEXXA may interfere with the anticoagulant effect of heparin. If anticoagulation is needed, use an alternative anticoagulant to heparin.

ADVERSE REACTIONS

The most common adverse reactions (≥ 5%) in bleeding subjects receiving ANDEXXA were urinary tract infections and pneumonia. The most common adverse reactions (≥ 3%) in healthy volunteers treated with ANDEXXA were infusion-related reactions.

INDICATION

ANDEXXA® (coagulation factor Xa [recombinant], inactivated-zhzo) is a recombinant modified human factor Xa (FXa) protein indicated for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

This indication is approved under accelerated approval based on the change from baseline in anti-FXa activity in healthy volunteers. An improvement in hemostasis has not been established. Continued approval for this indication may be contingent upon the results of studies that demonstrate an improvement in hemostasis in patients.

Limitations of Use

ANDEXXA has not been shown to be effective for, and is not indicated for, the treatment of bleeding related to any FXa inhibitors other than apixaban or rivaroxaban.

Please see full Important Safety Information throughout and accompanying full Prescribing Information, including Boxed WARNING.

You are encouraged to report negative side effects of AstraZeneca prescription drugs by calling 1-800-236-9933. If you prefer to report these to the FDA, call 1-800-FDA-1088.

REFERENCE: ANDEXXA® (coagulation factor Xa [recombinant], inactivated-zhzo) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2023.

This program is intended for US healthcare professionals only.

AstraZeneca will comply with any and all federal or state reporting requirements regarding any value or expense associated with this event. AstraZeneca fully supports and abides by the PhRMA Code on Interactions with Healthcare Professionals (HCPs). This program is open only to HCP invitees. AstraZeneca will not accommodate attendance of a spouse or other guest of any HCP attendee, nor will AstraZeneca pay for transportation or parking costs of attendees. If you are a prescriber and/or a federal, state, or institution employee, you may be subject to laws, regulations or rules which prohibit or limit your receipt of gifts, meals, or items of value. We ask that you comply with any such restrictions.

AstraZeneca will not recommend, endorse, or support the submission of this promotional program for CE credits.

AstraZeneca

To learn more about ANDEXXA, visit www.Andexxa.com

Andexxa® Coagulation Factor Xa (Recombinant), Inactivated-zhzo
THE ONLY FXA INHIBITOR ANTIDOTE